Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer

Hepato-Gastroenterology

Volumn 47, Issue 32, 2000, Pages 419-423

  Kitamura, Kaoru ^a   Saeki, Hiroshi ^a   Kawaguchi, Hidetoshi ^a   Araki, Koshi ^a   Ohno, Shinji ^a   Kuwano, Hiroyuki ^b   Maehara, Yoshihiko ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Biopsied specimen; Esophageal cancer; Immunohistochemical staining; Ki 67 antigen; p53 protein; Prediction test of treatment efficiency

Indexed keywords

CISPLATIN; KI 67 ANTIGEN; PROTEIN P53;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; DEVICE; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGUS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034003286     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. 1 Sugimachi K, Inokuchi K, Kuwano H, Kai H, Okamura T, Okudaira Y: Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet 1983; 157:537-540.
2. 2 Sugimachi K, Matsuda H, Ohno S, Fukuda A, Matsuoka M, Mori M, et al: Long-term effects of hyperthermia combined with chemotherapy and irradiation for the treatment of patients with carcinoma of the esophagus. Surg Gynecol Obstet 1988; 167:319-323.
3. 3 Kitamura K, Kuwano H, Watanabe M, Nozoe T, Yasuda M, Sumiyoshi K, et al: Prospective randomized study of hyperthermia combined with chemoradiotherapy for esophageal carcinoma. J Surg Oncol 1995; 60:55-58.
4. 4 Kitamura K, Kuwano H, Araki K, Egashira A, Kawaguchi H, Saeki H, et al: Clinicopathologic features of patients with esophageal cancer obtaining a histological complete response for preoperative hyperthermo-chemoradiotherapy. Int J Hyperthermia 1998; 14:233-243.
5. 5 Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutation in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-4878.
6. 6 Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine 1995; 1:1029-1034.
7. 7 Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood; 84:3148-57.
8. 8 Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31:13-20.
9. 9 Cattoretti G, Becker MKG, Duchrow M, Duchrow M, Schluter C, Galle J, et al: Monoclonal antibodies against recombinant part of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168:357-363.
10. 10 Japanese Society of Esophageal Diseases: Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. 8th Edition. Tokyo: Kanehara Inc., 1992; pp. 47-48. (In Japanese)
11. 11 Dixon WJ (Ed.): BMDP Statistical Software, University of California Press, Los Angeles 1992; pp. 1105-1144.
12. 12 Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, et al: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas Clin Cancer Res 1997; 3:593-600.
13. 13 Youssef EM, Matsuda T, Takada N, Osugi H, Higashino M, Kinoshita H, et al: Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995; 76:358-366.
14. 14 Righetti SC, Torre GD, Pilloti S, Menard S, Ottone F, Colnaghi MI, et al: A comparative study of p53 gene mutations, protein accumulation, and response to Cisplatin-based Chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56:689-693.
15. 15 Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996; 69:190-192.
16. 16 Stål O, Askmalm S, Wingren S Rutquist LE, Skog L, Ferraud L: P53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 1995; 34:767-770.
17. 17 Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, et al: Accumulation of p53 protein as a possible prediction of response to adjuvant combination chemotherapy with Cyclophosphamide, Methotrexate, Fluorouracil, and Predonisone for breast cancer. J Natl Cancer Inst 1995; 87:254-256.
18. 18 Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, et al: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54:5824-5830.